Last reviewed · How we verify
HyperAcute-Prostate Cancer Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
HyperAcute-Prostate Cancer Vaccine (HyperAcute-Prostate Cancer Vaccine) — NewLink Genetics Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HyperAcute-Prostate Cancer Vaccine TARGET | HyperAcute-Prostate Cancer Vaccine | NewLink Genetics Corporation | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HyperAcute-Prostate Cancer Vaccine CI watch — RSS
- HyperAcute-Prostate Cancer Vaccine CI watch — Atom
- HyperAcute-Prostate Cancer Vaccine CI watch — JSON
- HyperAcute-Prostate Cancer Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). HyperAcute-Prostate Cancer Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperacute-prostate-cancer-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab